secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001372514-25-000079
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling
--------------------------------------------------------------------------------

- Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.
- R&D expense $2.7M (net of $1.7M Théa reimbursement) vs $2.1M in Q3 2024.
- Q3 2025 net income $27K vs net loss of $3.4M in Q3 2024, driven by tax impacts and noncash gains.
- Both Phase 2 trials — KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa) — continue recruitment and dosing.
- Received $1.2M in reimbursed R&D from Théa in Q3; billed an additional $1.5M in the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000079/0001372514-25-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000079/kprx-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001372514-25-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer